Lung cancer: Maintenance therapy and precision medicine in NSCLC

Nature Reviews Clinical Oncology

Volumn 10, Issue 10, 2013, Pages 549-550

  Rosell, Rafael ^a   Karachaliou, Niki ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PEMETREXED; PLACEBO; THYMIDYLATE SYNTHASE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; INDUCTION CHEMOTHERAPY; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84885019527     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.152     Document Type: Short Survey

References (10)

1. Paz-Ares, L. et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 13, 247-255 (2012).
2. Barlesi, F. et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.42.3749.
3. Paz-Ares, L. G. et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012. 47.1102.
4. Karnofsky, D. A., Abelmann, W. H., Craver, L. F. & Burchenal, J. H. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma Cancer 1, 634-656 (1948).
5. Westeel, V. et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J. Natl Cancer Inst. 97, 499-506 (2005). (Pubitemid 40590431)
6. Scagliotti, G. V. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26, 3543-3551 (2008).
7. Nicolson, M. C. et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J. Thorac. Oncol. 8, 930-939 (2013).
8. Rosell, R., Bivona, T. G. & Karachaliou, N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet (in press).
9. Dominguez, C. L. et al. Diacylglycerol kinase alpha is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov. 3, 782-797 (2013).
10. Pullamsetti, S. S. et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene 32, 1121-1134 (2013).